EP1202750A4 - Method of treating hiv infection and related secondary infections thereof - Google Patents

Method of treating hiv infection and related secondary infections thereof

Info

Publication number: EP1202750A4
Authority: EP; European Patent Office
Prior art keywords: hiv infection; treating hiv; secondary infections; related secondary; infections
Prior art date: 1997-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP98918740A

Other languages

German (de)

French (fr)

Other versions

EP1202750A1 (en

Inventor

Arsinur Burcoglu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-28

Filing date

1998-04-28

Publication date

2002-10-16

1998-04-28 Application filed by Individual filed Critical Individual

2002-05-08 Publication of EP1202750A1 publication Critical patent/EP1202750A1/en

2002-10-16 Publication of EP1202750A4 publication Critical patent/EP1202750A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP98918740A 1997-04-28 1998-04-28 Method of treating hiv infection and related secondary infections thereof Withdrawn EP1202750A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US84801397A	1997-04-28	1997-04-28
US848013		1997-04-28
PCT/US1998/008357 WO1998048843A1 (en)	1997-04-28	1998-04-28	Method of treating hiv infection and related secondary infections thereof

Publications (2)

Publication Number	Publication Date
EP1202750A1 EP1202750A1 (en)	2002-05-08
EP1202750A4 true EP1202750A4 (en)	2002-10-16

Family

ID=25302109

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP98918740A Withdrawn EP1202750A4 (en)	1997-04-28	1998-04-28	Method of treating hiv infection and related secondary infections thereof

Country Status (5)

Country	Link
EP (1)	EP1202750A4 (en)
AU (1)	AU754242B2 (en)
CA (1)	CA2259041A1 (en)
HK (1)	HK1044896A1 (en)
WO (1)	WO1998048843A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2358385C (en)	1998-12-31	2013-08-06	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP2412242A3 (en)	2001-07-05	2012-06-13	Novartis Vaccines and Diagnostics, Inc.	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
MXPA04011941A (en) *	2002-05-31	2005-07-26	Univ Regensburg Klinikum	Method for the protection of endothelial and epithelial cells during chemotherapy.
ITMI20031714A1 (en) *	2003-09-05	2005-03-06	Gentium Spa	FORMATIONS FOR ANTITUMORAL ACTION.
AU2005216971A1 (en) *	2004-02-25	2005-09-09	Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Office Of Technology Transfer	Methylation inhibitor compounds
AU2007231651B2 (en) *	2005-03-03	2011-09-15	Gentium Spa	Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
EP1855697A2 (en) *	2005-03-03	2007-11-21	Gentium Spa	Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors
ITMI20050336A1 (en) *	2005-03-03	2006-09-04	Gentium Spa	FORMULATION FOR ANTI-TUMOR ACTIVITY
AU2010363814B2 (en)	2010-11-12	2016-05-19	Gentium S.R.L.	Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
CN104619857A (en)	2012-06-22	2015-05-13	真蒂奥姆有限公司	Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en)	2014-11-27	2016-06-01	Gentium S.p.A.	Cellular-based method for determining the potency of defibrotide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991017246A1 (en) *	1990-05-04	1991-11-14	Isis Pharmaceuticals, Inc.	Modulation of gene expression through interference with rna secondary structure
EP0558833A2 (en) *	1991-12-09	1993-09-08	Crinos Industria Farmacobiologica S.p.A.	New oligodeoxyribonucleotides having anti-ischemic activity and methods of preparation thereof
WO1994015621A1 (en) *	1993-01-13	1994-07-21	Arsinur Burcoglu	Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
WO1995004068A1 (en) *	1993-07-29	1995-02-09	Isis Pharmaceuticals, Inc.	Oligomers for modulating human immunodeficiency virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1170214B (en) *	1983-09-12	1987-06-03	Crinos Industria Farmaco	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PERIPHERAL ARTERIOPATHIES
IT1170215B (en) *	1983-09-12	1987-06-03	Crinos Industria Farmaco	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF STATES OF ACUTE RENAL INSUFFICIENCY
IT1206341B (en) *	1984-02-16	1989-04-14	Crinos Industria Farmaco	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE MYOCARDIUM ISCHHEMIA.

1998
- 1998-04-28 EP EP98918740A patent/EP1202750A4/en not_active Withdrawn
- 1998-04-28 CA CA002259041A patent/CA2259041A1/en not_active Abandoned
- 1998-04-28 AU AU71609/98A patent/AU754242B2/en not_active Ceased
- 1998-04-28 WO PCT/US1998/008357 patent/WO1998048843A1/en not_active Application Discontinuation
2002
- 2002-09-04 HK HK02106517.9A patent/HK1044896A1/en unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991017246A1 (en) *	1990-05-04	1991-11-14	Isis Pharmaceuticals, Inc.	Modulation of gene expression through interference with rna secondary structure
EP0558833A2 (en) *	1991-12-09	1993-09-08	Crinos Industria Farmacobiologica S.p.A.	New oligodeoxyribonucleotides having anti-ischemic activity and methods of preparation thereof
WO1994015621A1 (en) *	1993-01-13	1994-07-21	Arsinur Burcoglu	Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
WO1995004068A1 (en) *	1993-07-29	1995-02-09	Isis Pharmaceuticals, Inc.	Oligomers for modulating human immunodeficiency virus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRACHT ET AL: "Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 200, no. 2, 29 April 1994 (1994-04-29), pages 933 - 937, XP002112704, ISSN: 0006-291X *
HIZAL NURPERI ET AL: "Investigation of the fibrinolytic activity of defibrotide fractions.", GENERAL PHARMACOLOGY, vol. 25, no. 8, 1994, pages 1617 - 1620, XP008007140, ISSN: 0306-3623 *
See also references of WO9848843A1 *

Also Published As

Publication number	Publication date
HK1044896A1 (en)	2002-11-08
EP1202750A1 (en)	2002-05-08
CA2259041A1 (en)	1998-11-05
AU754242B2 (en)	2002-11-07
AU7160998A (en)	1998-11-24
WO1998048843A1 (en)	1998-11-05

Publication	Publication Date	Title
IL129352A0 (en)	2000-02-17	Benzimidazole-2- carbamates for the treatment of viral infections and cancer
EP0831873A4 (en)	2002-07-17	The treatment of hiv and other viral infections using combinatory therapy
IL139002A0 (en)	2001-11-25	Compositions for the treatment of hiv and other viral infections
HK1023371A1 (en)	2000-09-08	Compositions and methods for treating viral infections
PL335160A1 (en)	2000-04-10	Treatment of hiv and carcinoma
AU8452698A (en)	1999-02-16	Industrial fabrics and method of treatment
EP0569703A3 (en)	1994-10-26	Method of treating and preventing viral infections using HBNF and MK protein.
HK1044896A1 (en)	2002-11-08	Method of treating hiv infection and related secondary infections thereof
PL312908A1 (en)	1996-09-02	Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors
GB9304746D0 (en)	1993-04-28	Treatment of viral infections
EP0726775A4 (en)	1999-03-31	Vaccine and method for treatment of chlamydial infections
EP0921803A4 (en)	2003-04-02	Methods for preventing and treating pestivirus infection and associated diseases
ZA9510108B (en)	1996-06-06	Composition and method for prevention and treatment of HIV-1 infection
AU4602897A (en)	1998-04-24	Method for treatment of immunodeficiency virus infection
IL116925A (en)	2000-07-26	Combinations of compounds useful for treating HIV infections and pharmaceutical compositions comprising these combinations
ZA972722B (en)	1997-10-23	Method for prevention and treatment of viral infectious diseases.
EP0789565A4 (en)	1999-03-24	Prevention of hiv infection
AU2473695A (en)	1995-11-29	Method of slowing the progression of hiv infection
PL317876A1 (en)	1997-04-28	Combined treatment of hiv infections
AU3530395A (en)	1996-04-19	Treatment of viral infections
AU3553195A (en)	1996-04-26	Methods of identifying agents which block hiv infection
AU6605196A (en)	1997-09-16	Method of treating hepatitis delta virus infection
AU5085693A (en)	1994-03-15	Method of treating epstein-barr virus infection
AU6559194A (en)	1994-11-08	Method of treating hepatitis b infection
AU2001288870A1 (en)	2002-03-22	Antiviral compounds and method of treating viral infections

Legal Events

Date	Code	Title	Description
2002-03-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2002-05-08	17P	Request for examination filed	Effective date: 19990121
2002-05-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK FR GB IT LI NL SE
2002-10-16	A4	Supplementary search report drawn up and despatched	Effective date: 20020903
2002-10-16	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK FR GB IT LI NL SE
2004-10-27	17Q	First examination report despatched	Effective date: 20040909
2007-03-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2007-04-25	18D	Application deemed to be withdrawn	Effective date: 20060916
2016-11-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1044896 Country of ref document: HK